Oppenheimer & Co. Inc. Purchases New Position in Vaxcyte, Inc. (NASDAQ:PCVX)

Oppenheimer & Co. Inc. bought a new position in Vaxcyte, Inc. (NASDAQ:PCVX) in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor bought 4,459 shares of the company’s stock, valued at approximately $510,000.

A number of other large investors have also added to or reduced their stakes in PCVX. Riverview Trust Co acquired a new position in shares of Vaxcyte in the third quarter worth approximately $27,000. Blue Trust Inc. boosted its position in shares of Vaxcyte by 33.5% during the 3rd quarter. Blue Trust Inc. now owns 371 shares of the company’s stock valued at $42,000 after purchasing an additional 93 shares in the last quarter. Fifth Third Bancorp acquired a new stake in Vaxcyte during the second quarter worth approximately $35,000. J.Safra Asset Management Corp increased its holdings in Vaxcyte by 649.4% in the second quarter. J.Safra Asset Management Corp now owns 607 shares of the company’s stock worth $46,000 after purchasing an additional 526 shares in the last quarter. Finally, Quest Partners LLC acquired a new position in Vaxcyte in the second quarter valued at approximately $70,000. Institutional investors own 96.78% of the company’s stock.

Insider Transactions at Vaxcyte

In related news, CEO Grant Pickering sold 2,366 shares of the firm’s stock in a transaction that occurred on Thursday, November 7th. The shares were sold at an average price of $103.89, for a total transaction of $245,803.74. Following the completion of the sale, the chief executive officer now owns 137,398 shares of the company’s stock, valued at $14,274,278.22. This trade represents a 1.69 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Andrew Guggenhime sold 42,000 shares of the business’s stock in a transaction on Friday, October 18th. The shares were sold at an average price of $115.39, for a total transaction of $4,846,380.00. Following the sale, the chief financial officer now owns 90,383 shares of the company’s stock, valued at approximately $10,429,294.37. This represents a 31.73 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 117,464 shares of company stock worth $12,640,276. Company insiders own 3.10% of the company’s stock.

Vaxcyte Price Performance

Shares of PCVX stock opened at $85.96 on Thursday. The company’s fifty day simple moving average is $108.95 and its two-hundred day simple moving average is $89.11. Vaxcyte, Inc. has a 1 year low of $48.24 and a 1 year high of $121.06. The stock has a market capitalization of $10.71 billion, a price-to-earnings ratio of -18.69 and a beta of 1.01.

Vaxcyte (NASDAQ:PCVX) last released its earnings results on Tuesday, November 5th. The company reported ($0.83) EPS for the quarter, beating analysts’ consensus estimates of ($1.10) by $0.27. During the same period in the prior year, the firm posted ($0.91) earnings per share. Equities research analysts anticipate that Vaxcyte, Inc. will post -4.14 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on the stock. Leerink Partners raised their price target on shares of Vaxcyte from $106.00 to $153.00 and gave the stock an “outperform” rating in a report on Tuesday, September 3rd. Needham & Company LLC reaffirmed a “buy” rating and set a $140.00 price target on shares of Vaxcyte in a research note on Wednesday, November 6th. BTIG Research boosted their price objective on Vaxcyte from $98.00 to $160.00 and gave the company a “buy” rating in a report on Tuesday, September 3rd. Mizuho increased their target price on Vaxcyte from $113.00 to $163.00 and gave the stock an “outperform” rating in a report on Tuesday, September 10th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Vaxcyte in a research note on Wednesday, November 6th. Seven research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $147.50.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.